Huakang Biomedical Holdings Company Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, the Group is expected to record a loss attributable to owners of the Company of approximately RMB 2.0 million for the six months ended 30 June 2021 representing a significant decrease in loss of approximately RMB 4.1 million comparing with the six months ended 30 June 2020 of a loss attributable to owners of the Company of approximately RMB 6.1 million.